Icon
ICON PLC is a global clinical research organization providing outsourced development services to the pharmaceutical, biotechnology, and medical device industries. The company offers clinical trial management, drug development strategy, laboratory testing, regulatory consulting, and post-market surveillance capabilities. Revenue is principally generated through service contracts covering phase one through four clinical trials and specialized clinical research support. Its end markets consist of global pharmaceutical corporations, biotechnology startups, and medical device developers seeking operational expertise for clinical testing. As one of the largest contract research organizations globally, ICON holds a major market position in international biopharmaceutical development services. The company is headquartered in Dublin, Ireland, and its ordinary shares are publicly traded on the Nasdaq Stock Market.
10 of the funds FundTelligence covers report a position in Icon.
- Legal name
- ICON PLC
- Sector
- Health Care
- Country
- Ireland
- Funds holding it
- 10
Funds holding Icon
- Fondsfinans Global Utbytte — Fondsfinans · 4.53 % (full portfolio disclosed, October 2026)
- Fondsfinans Global Helse — Fondsfinans · 4.47 % (full portfolio disclosed, October 2026)
- Fidelity US Smaller Companies Fund — Fidelity · 3.0 % (largest positions only, September 2026)
- Handelsbanken Infrastruktur och Beredskap — Handelsbanken · 0.77 % (full portfolio disclosed, October 2026)
- TRP Global Value Equity Fund — T. Rowe Price · 0.75 % (full portfolio disclosed, September 2026)
- T. Rowe Price Global Value Equity Fund — T. Rowe Price · 0.74 % (full portfolio disclosed, September 2026)
- Swedbank Robur Healthcare — Swedbank · 0.55 % (full portfolio disclosed, October 2026)
- Handelsbanken Europa Index Criteria — Handelsbanken · 0.44 % (full portfolio disclosed, October 2026)
Showing the 8 largest of 10 funds holding it.